Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 7/20 | 0.73 |
| ▸ | TPO | P07202 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14936931 | 0.99 | MPO (0.72) | MPOTPOGAATLR9MAPK1 | |
| SCHEMBL14947053 | 0.94 | MPO (0.76) | MPOTPOGAATLR9MAPK1 | |
| Formic Acid SCHEMBL14936140 | 0.89 | MPO (0.72) | MPOTPOGAATLR9MAPK1 | |
| SCHEMBL14935951 | 0.88 | MPO (0.77) | MPOTPOGAAMAPK1KDM4E | |
| SCHEMBL14947054 | 0.87 | MPO (0.87) | MPOTPOGAAMAPK1KDM4E | |
| SCHEMBL14937141 | 0.87 | MPO (0.87) | MPOTPOGAAMAPK1KDM4E | |
| SCHEMBL14936613 | 0.86 | MPO (0.85) | MPOTPOGAAMAPK1KDM4E | |
| SCHEMBL14947058 | 0.86 | MPO (0.85) | MPOTPOGAAMAPK1KDM4E | |
| SCHEMBL14936666 | 0.85 | MPO (0.80) | MPOTPOGAAMAPK1KDM4E | |
| SCHEMBL14936868 | 0.85 | MPO (0.73) | MPOTPOGAAMAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873673-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873673-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20160304469-A1 | 2-Thiopyrimidinones | PFIZER INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160304469-A1 | 2-Thiopyrimidinones | PFIZER INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-9399626-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-9399626-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-20140288049-A1 | 2-Thiopyrimidinones | PFIZER (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288049-A1 | 2-Thiopyrimidinones | PFIZER (US) | 2014-09-25 | — | — | US | disclosed |
| US-8841314-B2 | 2-Thiopyrimidinones | PFIZER INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841314-B2 | 2-Thiopyrimidinones | PFIZER INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8835449-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835449-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20130296351-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-11-07 | — | — | US | disclosed |
| US-20130296351-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-11-07 | — | — | US | disclosed |
| US-20130123230-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-05-16 | — | — | US | disclosed |
| US-20130123230-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123230-A1 | 2-Thiopyrimidinones | MPO, SERPINB1, TNNI3 | MPO 1/4885TPO 32/4885GAA 162/4885 |
| US-20160304469-A1 | 2-Thiopyrimidinones | MPO, SERPINB1, TNNI3 | MPO 1/4885TPO 32/4885GAA 162/4885 |
| US-20140288049-A1 | 2-Thiopyrimidinones | MPO, SERPINB1, TNNI3 | MPO 1/4885TPO 32/4885GAA 162/4885 |
| US-20130296351-A1 | 2-Thiopyrimidinones | MPO, SERPINB1, TNNI3 | MPO 1/4885TPO 32/4885GAA 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.